OIS Sets Sights on Anterior Segment Innovations

OIS Sets Sights on Anterior Segment Innovations
The second annual Ophthalmology Innovation Summit (OIS) at the 2013 ASCRS•ASOA Symposium & Congress combined industry, clinicians, and entrepreneurs to highlight innovations in anterior segment surgery.

The half-day session featured talks on the impact of femtosecond lasers and intraoperative aberrometry, as well as micro-invasive glaucoma surgery (MIGS).

Co-chairman William J. Link, PhD, Versant Ventures, Menlo Park, Calif., gave a talk on the status and impact of innovation in the ophthalmic world, and said a key criteria driving innovation is that technology has to be real and useful.

“Acquisitions have been quiet. Venture capital is dwindling,”

he said, but the size and demographic of the market is “amazing.”

“Multiple venture firms care about ophthalmology and are investing in the space,”

Mr. Link said. “Innovation is directed where it is rewarded.”

Another market being tracked carefully right now is dry eye, he added.

“I think we’ll see more innovation there,” Mr. Link said. In the refractive space, Mr. Link predicted that corneal inlays will spur innovation as well.

This is the first time that there is alignment in cataract, refractive and glaucoma spaces. “We’ve got rocket power now driving the field,” Mr. Link said. “We have unprecedented innovations. When we do well, many people benefit.”

SHARE THIS ARTICLE WITH YOUR COLLEAGUES:

RECOMMENDED FOR YOU

Novartis-Regeneron Dispute Enters a New Phase

Novartis-Regeneron Dispute Enters a New Phase

The Myopia Management Market How Big is Big Web

The Myopia Management Market: ‘How Big is Big?’

Despite Interruption, Pixium Vision Aims to Keep Moving Toward Commercializing Prima System (1)

Despite Interruption, Pixium Vision Aims to Keep Moving Toward Commercializing Prima System

Gyroscope Therapeutics Completes Financing to Advance Gene Therapy Candidate for GA

Gyroscope Therapeutics Completes Financing to Advance Gene Therapy Candidate for GA

Article Graphic for Anterior Clinical Panel Web

Anterior Segment Advances That ‘Won’ 2020 and Those Poised To Disrupt the Future

With $36 Million, Visus Starts Phase II Trial of Presbyopia Drop Brimochol Web

With $36 Million, Visus Starts Phase II Trial of Presbyopia Drop Brimochol

About The Author

Tom Salemi

Tom serves as Content Director for Healthegy, joining the company in 2014, to create and manage a new line of podcasts, publications and other editorial products. At Healthegy, Tom hosts the OIS Podcast and MedtechTalk, contributes to the Engage and Eye on Innovation newsletters and assists in the agenda development of new and existing conferences.

SUBSCRIBE TO OUR NEWSLETTER

Get The Latest News In Opthalmologic Innovation To Your Inbox.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.

SUBSCRIBE TO OIS WEEKLY

Get our monthly newsletter about the latest in opthalmologic innovation.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.

STAY CONNECTED

PODCASTS